DRMA Dermata Therapeutics, Inc. Stock Quote

DRMA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.26	Insider Own	1.40%	Shs Outstand	8.33M	Perf Week	0.69%
Market Cap	5.75M	Forward P/E	-	EPS next Y	-1.41	Insider Trans	0.00%	Shs Float	4.28M	Perf Month	-38.07%
Income	-10.50M	PEG	-	EPS next Q	-0.40	Inst Own	1.30%	Short Float	0.89%	Perf Quarter	-41.26%
Sales	-	P/S	-	EPS this Y	-223.30%	Inst Trans	-20.47%	Short Ratio	0.32	Perf Half Y	-84.87%
Book/sh	1.21	P/B	0.61	EPS next Y	40.60%	ROA	-149.00%	Target Price	9.00	Perf Year	-
Cash/sh	1.39	P/C	0.53	EPS next 5Y	-	ROE	-183.70%	52W Range	0.62 - 6.95	Perf YTD	-57.47%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-89.01%	Beta	-
Dividend %	-	Quick Ratio	7.70	Sales past 5Y	-	Gross Margin	-	52W Low	23.23%	ATR	0.14
Employees	8	Current Ratio	7.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.87	Volatility	28.68% 16.51%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.99	Prev Close	0.74
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	118.03K	Price	0.76
Recom	2.00	SMA20	-20.59%	SMA50	-29.90%	SMA200	-72.00%	Volume	106,419	Change	3.23%

May-16-22 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results ACCESSWIRE -9.71%
Apr-25-22 04:50PM	Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules ACCESSWIRE
Apr-21-22 09:00AM	Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules ACCESSWIRE
Mar-28-22 08:30AM	Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results ACCESSWIRE
Mar-24-22 08:30AM	Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference ACCESSWIRE
Feb-10-22 07:27AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday InvestorPlace +32.71%
Feb-07-22 08:58AM	Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know Benzinga -34.68%
Jan-13-22 08:30AM	Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors ACCESSWIRE
Jan-05-22 08:30AM	Dermata to Present at the H.C. Wainwright BioConnect Conference ACCESSWIRE -6.43%
Nov-22-21 05:06AM	Companies Like Dermata Therapeutics (NASDAQ:DRMA) Are In A Position To Invest In Growth Simply Wall St. -26.89%
04:53AM	52 Biggest Movers From Friday Benzinga
Nov-19-21 02:17PM	Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why Benzinga -30.17%
08:30AM	Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions ACCESSWIRE
Nov-17-21 08:00AM	Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea ACCESSWIRE
Nov-15-21 04:01PM	Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update ACCESSWIRE
Nov-12-21 08:00AM	Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting ACCESSWIRE
Nov-11-21 06:00AM	Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions ACCESSWIRE
Oct-19-21 07:00AM	18 Stocks Moving in Tuesday's Pre-Market Session Benzinga
06:53AM	Dermata Stock Jumps On Positive Psoriasis Candidate Data Benzinga

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience